The Metabolic Indices of Persons with First-Episode Schizophrenia on Antipsychotic Medications: A 12-Week Follow-up Study

A bstract Background: Metabolic changes are a major limitation to antipsychotic medications, especially the second-generation ones. However, longitudinal studies on neuroleptic-naïve persons with first-episode schizophrenia are sparse in Sub-Saharan Africa. Objective: To determine the effect of antipsychotic medications on the metabolic indices of patients with first-episode schizophrenia. Materials and Methods: This was a follow-up study involving 64 persons with first-episode schizophrenia who met the eligibility criteria. Diagnosis of schizophrenia was made using the mini international neuropsychiatric interview psychotic disorder module. Metabolic indices examined were lipid profile [i.e., total cholesterol (TC), triglycerides, low-density lipoprotein (LDL), and high-density lipoprotein (HDL)], fasting blood glucose (FBG), waist–hip ratio (WHR), and body mass index. Changes in the metabolic indices across the intervals of follow-up were analyzed using repeated-measures analysis of variance with post hoc comparison. Results: All the metabolic indices indicated a significant increase at each interval of follow-up ( P < 0.001), such as TC ( F = 174.63, P < 0.001), HDL ( F = 124.27, P < 0.001), LDL ( F = 63.09, P < 0.001), very low-density lipoprotein (VLDL) ( F = 71.37, P = 0.008), FBG ( F = 62.90, P < 0.001), and WHR ( F = 65.13, P < 0.001). Interestingly, scores in VLDL ( t = 2.40, P = 0.01) and WHR ( t = 2.64, P = 0.01) were significantly higher in participants using typical antipsychotics when compared with those using atypical antipsychotics. Conclusion: Antipsychotic medications significantly increase the risk of metabolic abnormalities in patients. Regular monitoring and a multidisciplinary approach to management are needed. Patients should be regularly monitored for weight gain, high glucose levels, and abnormal lipid profiles, especially in the initial months of treatment. Patient education on diet and lifestyle changes is crucial to address weight gain.

Authors

Institutions

Publication Details

Journal
International Journal of Medicine and Health Development
Published
2025-06-27
DOI
https://doi.org/10.4103/ijmh.ijmh_97_24
Primary Topic
Schizophrenia research and treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Metabolic Indices of Persons with First-Episode Schizophrenia on Antipsychotic Medications: A 12-Week Follow-up Study

Chinyere Okeke, Temitope I. Olatayo, Theclar Ogochukwu Iyidobi, Justus Uchenna Onu et al.
International Journal of Medicine and Health Development
Schizophrenia research and treatment
article

The Metabolic Indices of Persons with First-Episode Schizophrenia on Antipsychotic Medications: A 12-Week Follow-up Study

Chinyere Okeke, Temitope I. Olatayo, Theclar Ogochukwu Iyidobi, Justus Uchenna Onu, Samuel Ghasi, Tobechukwu C. Iyidobi, Rosemary C. Muomah, Ngozichukwu N. Unaogu, Paul C. Odinka
article en

Abstract

A bstract Background: Metabolic changes are a major limitation to antipsychotic medications, especially the second-generation ones. However, longitudinal studies on neuroleptic-naïve persons with first-episode schizophrenia are sparse in Sub-Saharan Africa. Objective: To determine the effect of antipsychotic medications on the metabolic indices of patients with first-episode schizophrenia. Materials and Methods: This was a follow-up study involving 64 persons with first-episode schizophrenia who met the eligibility criteria. Diagnosis of schizophrenia was made using the mini international neuropsychiatric interview psychotic disorder module. Metabolic indices examined were lipid profile [i.e., total cholesterol (TC), triglycerides, low-density lipoprotein (LDL), and high-density lipoprotein (HDL)], fasting blood glucose (FBG), waist–hip ratio (WHR), and body mass index. Changes in the metabolic indices across the intervals of follow-up were analyzed using repeated-measures analysis of variance with post hoc comparison. Results: All the metabolic indices indicated a significant increase at each interval of follow-up ( P < 0.001), such as TC ( F = 174.63, P < 0.001), HDL ( F = 124.27, P < 0.001), LDL ( F = 63.09, P < 0.001), very low-density lipoprotein (VLDL) ( F = 71.37, P = 0.008), FBG ( F = 62.90, P < 0.001), and WHR ( F = 65.13, P < 0.001). Interestingly, scores in VLDL ( t = 2.40, P = 0.01) and WHR ( t = 2.64, P = 0.01) were significantly higher in participants using typical antipsychotics when compared with those using atypical antipsychotics. Conclusion: Antipsychotic medications significantly increase the risk of metabolic abnormalities in patients. Regular monitoring and a multidisciplinary approach to management are needed. Patients should be regularly monitored for weight gain, high glucose levels, and abnormal lipid profiles, especially in the initial months of treatment. Patient education on diet and lifestyle changes is crucial to address weight gain.

International Journal of Medicine and Health DevelopmentVol. 30(3)
University of Nigeria (NG), Nnamdi Azikiwe University (NG), Federal Neuro Psychiatric Hospital (NG), University of Nigeria Teaching Hospital (NG)
Openalex Percentile: Top 82%
Schizophrenia research and treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.